Free  A change of paradigm

Marketing Authorisations

Risdiplam (Evrysdi°) in spinal muscular atrophy

Liraglutide (Saxenda°) in obesity in adolescents

Editors' opinion. A pipe dream

Tocilizumab (Roactemra°) in severe covid-19

Cannabidiol (Epidyolex°) in epilepsy associated with tuberous sclerosis complex

Pembrolizumab (Keytruda°) in relapsed or refractory Hodgkin lymphoma

Ipilimumab (Yervoy°) + nivolumab (Opdivo°) in certain inoperable pleural mesotheliomas

Ravulizumab (Ultomiris°) in atypical haemolytic uraemic syndrome

Ravulizumab (Ultomiris°) in paroxysmal nocturnal haemoglobinuria

Meningococcal group A, C, W, and Y vaccine (Menquadfi°) from the age of 12 months

Anakinra (Kineret°) in severe covid-19

Berotralstat (Orladeyo°) in hereditary angioedema

Adverse Effects

Messenger RNA covid-19 vaccines: a review of known adverse effects, as of mid-2022

Desloratadine: seizures in children

Sublingual buprenorphine: dental caries

Olmesartan: autoimmune hepatitis

Opioids: sudden death

Common stem: -gliptin

Outlook

Editors' opinion. Etifoxine "perhaps not lacking efficacy": when doubt benefits the company, and not patients

Etifoxine: no justification for keeping it on the market

"Denigration" of Plavix° generics: France's National Health Insurance System wins one round against Sanofi

A company fined for abuse of its dominant position

Masthead

Free  Masthead